Evidence map›Paper›PMID 40034298›Full record

ArticleHeliyon2025

Bioactive small compounds effectively inhibit ChREBP overexpression to treat NAFLD and T2DM: A computational drug development approach.

Hiron Saraj Devnath, Maisha Maliha Medha, Md Naharul Islam, Partha Biswas, Debasree Sen Oisay, Arafat Hossain, Rubaet Sharmin Ema, Md Mohaimenul Islam Tareq, Mimi Golder, Md Nazmul Hasan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hiron Saraj DevnathPharmacy Discipline, Khulna University, Khulna, 9208, Bangladesh.
Maisha Maliha MedhaPharmacy Discipline, Khulna University, Khulna, 9208, Bangladesh.
Md Naharul IslamPharmacy Discipline, Khulna University, Khulna, 9208, Bangladesh.
Partha BiswasLaboratory of Pharmaceutical Biotechnology and Bioinformatics, Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jashore, 7408, Bangladesh.
Debasree Sen OisayPharmacy Discipline, Khulna University, Khulna, 9208, Bangladesh.
Arafat HossainBiochemistry and Molecular Biology Department, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalgonj, 8100, Bangladesh.
Rubaet Sharmin EmaPharmacy Discipline, Khulna University, Khulna, 9208, Bangladesh.
Md Mohaimenul Islam TareqLaboratory of Pharmaceutical Biotechnology and Bioinformatics, Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jashore, 7408, Bangladesh.
Mimi GolderPharmacy Discipline, Khulna University, Khulna, 9208, Bangladesh.
Md Nazmul HasanLaboratory of Pharmaceutical Biotechnology and Bioinformatics, Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jashore, 7408, Bangladesh.
Biswajit BiswasDepartment of Pharmacy, Faculty of Biological Science and Technology, Jashore University of Science and Technology, Jashore, 7408, Bangladesh.
Samir Kumar SadhuPharmacy Discipline, Khulna University, Khulna, 9208, Bangladesh.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A glucose-dependent carbohydrate-signaling gene regulator named Carbohydrate response element binding protein (ChREBP), has recently been discovered as a major metabolic regulator of enzymes involved in the progression of non-alcoholic fatty liver disease (NAFLD) and type-II diabetes mellitus (T2DM). As a result, this research is aimed to identify natural small molecules as drug candidates that target the ChREBP in order to counter aggressive NAFLD and T2DM. A comprehensive

Indexed as

ChREBP-targeted therapyInsulin resistanceMolecular dynamic simulationNAFLDT2DM

Identifiers

PMID40034298
PMCPMC11872590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.